News/Blog
Read about our latest news:
ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer
Tuesday, May 24, 2022 8:00 AM https://www.accesswire.com/viewarticle.aspx?id=702335 ENB-003 is a first in class small molecule therapeutic selectively targeting the ETB receptor - a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / May 24, 2022 / ENB Therapeutics,...
ENB Therapeutics Demonstrated Early Efficacy in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab
Monday, February 1, 2021 8:00 AM https://www.accesswire.com/viewarticle.aspx?id=626781 ENB-003 is the Company's first in class small molecule therapeutic selectively targeting the ETB receptor - a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / February 1, 2021...
Early efficacy signals in ovarian cancer patients in ongoing Ph1 trial: Poster reporting findings presented at SITC 2020 Annual Meeting
ENB Therapeutics reports preliminary data from the ongoing Phase 1/2 trial assessing the safety and efficacy of lead product ENB-003 in combination with pembrolizumab. Safety data are encouraging with no significant drug related safety events from the first 3 dosing...
ENB Therapeutics Announces Successful Completion of the First Dosing Cohort in Phase 1 Clinical Trial of ENB-003 in Combination with Pembrolizumab
Monday, June 15, 2020 3:45 PMENB-003 is the Company's first in class small molecule therapeutic selectively targeting the ETB receptor - a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / June 15, 2020 / ENB Therapeutics, INC., a biotechnology company pioneering a...
IND approval received for lead product ENB-003
January 17, 2020 ENB Therapeutics receives IND approval from the FDA for our Phase 1/2 trial evaluating the safety and efficacy of lead product ENB-003 in combination with pembrolizumab. This is a major milestone for ENB and allows our clinical trial to be initiated...
ENB Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ENB-003 in combination with KEYTRUDA® (pembrolizumab) for Advanced Solid Tumors
New York, NY., February 4th, 2019 -- ENB Therapeutics, Inc., a clinical-stage, biopharmaceutical company developing innovative, endothelin-based oncologics, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD...
ENB Therapeutics Closes Series A Round of Funding
New York, NY, September 20, 2018: ENB Therapeutics Inc., a biopharmaceutical company pioneering pathways in endothelin-based oncologics, today announced that it has closed its Series A private equity financing. Proceeds from the financing will be used to advance the...
ENB to present at 2016 Pitch Fest organized by New York Bio
ENB was selected as one of 33 companies to present at this year's Pitch Fest on May 11th, at the New York Bio Annual Conference. The conference is being held at NYC's Time Warner Center. Representative entrepreneurs will give a 15-minute pitch to a panel of judges...
ENB CSO and Co-founder Dr. Sumayah Jamal wins Best-in-show at 1st Pitch Life Science NYC
April, 2016 1st Pitch Life Science is organized by MABA (Mid Atlantic Bio Angels (www.bioangels.net), a life science investor group, to encourage and educate aspiring life science entrepreneurs who want the opportunity to practice their pitch and to receive...
ENB Therapeutics accepted for presentation at the 2016 HemOnc Today Melanoma Conference in NYC
March, 2016 ENB Therapeutics presents poster entitled "Development of ENB-001 for the Treatment of Melanoma Brain Metastasis" at the 2016 HemOnc Today Melanoma and Cutaneous Malignancies Meeting in NYC. The meeting draws more than 250 colleagues and renowned speakers...